4 / 25
Patients at Risk
Ipilimumab
1861
839
370
254
192
170
120
26
15
5
0
Proportion of patients alive (%)
0
10
20
30
40
50
60
70
80
90
100
Months
0
12
24
36
48
60
72
84
96
108
120
Median OS, months (95% CI): 11.4 (10.7–12.1)
3-year OS rate, % (95% CI): 22 (20–24)
Ipilimumab
CENSORED
Pooled OS Analysis Including EAP
Data: 4846 Patients
Schadendorf D, et al. Presented at ECC 2013: oral 24LBA